Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced a new settlement and license agreement with Regeneron and Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world, which follows an earlier settlement covering the United States and Canada. This agreement clears the way for Biocon Biologics to commercialize Yesafili, a biosimilar Aflibercept (40mg/ml), in all countries worldwide. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions. It is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

See Full Page